Dactinomycin resources

DRUG INFO
Dactinomycin

Drug Name: Dactinomycin


Indication: For the treatment of Wilms' tumor, childhood rhabdomyosarcoma, Ewing's sarcoma and metastatic, nonseminomatous testicular cancer as part of a combination chemotherapy and/or multi-modality treatment regimen



Pharmacology: Generally, the actinomycins exert an inhibitory effect on gram-positive and gram-negative bacteria and on some fungi. However, the toxic properties of the actinomycins (including dactinomycin) in relation to antibacterial activity are such as to preclude their use as antibiotics in the treatment of infectious diseases. Because the actinomycins are cytotoxic, they have an antineoplastic effect which has been demonstrated in experimental animals with various types of tumor implant. This cytotoxic action is the basis for their use in the treatment of certain types of cancer. Dactinomycin is believed to produce its cytotoxic effects by binding DNA and inhibiting RNA synthesis.

Mechanism Of Action: Good evidence exists that this drug bind strongly, but reversibly, to DNA, interfering with synthesis of RNA and, consequently, with protein synthesis.

Drug Category: Antibiotics; Anti-bacterial Agents; Antineoplastic Agents; ATC:L01DA01

Brand Names/Synonyms: -Pentone; A1410; ACT; ACT D; ACTINOMYCIN D; ACTO-D; AD; Actactinomycin a Iv; Actinomycin 11 Cosmegen; Actinomycin 7; Actinomycin Aiv; Actinomycin C1; Actinomycin D; Actinomycin I; Actinomycin I1; Actinomycin Iv; Actinomycin X 1; Actinomycindioic D Acid, D

Dosage Forms: Injectable and parenteral solution

Absorption: poorly absorbed from gastrointestinal tract

Interactions: DrugBank: Interactions for Dactinomycin

Interactions for Dactinomycin:

Drug/LaboratoryTest Interactions

Dactinomycin may interfere with bioassay procedures for the determination of antibacterial drug levels.





Chemical IUPAC Name: 8-amino-N-(2-amino-4,6-dimethyl-3-oxo-phenoxazin-1-yl)carbonyl-N'-[8-amino-4,6-dimethyl-7-oxo-9-[[3,6,10-trimethyl-7,14-bis(1-methylethyl)-2,5,8,12,15-pentaoxo-9-oxa-3,6,13,16-tetrazabicyclo[14.3.0]nonadec-11-yl]carbamoyl]phenoxazin-1-yl]carbonyl-4,6-dimethyl-7-oxo-N,N'-bis[3,6,10-trimethyl-7,14-bis(1-methylethyl)-2,5,8,12,15-pentaoxo-9-oxa-3,6,13,16-tetrazabicyclo[14.3.0]nonadec-11-yl]-1,9-bis[[3,6,10-trimethyl-7,14-bis(1-methylethyl)-2,5,8,12,15-pentaoxo-9-oxa-3,6,13,16-tetrazabicyclo[14.3.0]nonadec-11-yl]carbamoyl]phenoxazine-1,9-dicarboxamide

Chemical Formula: C62H86N12O16

Half Life: 36 hours

Drug Type: Approved Drug

# Accession No: APRD00124

CAS Registry Number: 50-76-0